Rituximab biosimilar (CTTQ Pharma)

利妥昔单抗生物类似药（正大天晴）

Report date: 2025/03/26 11:26:54

Base Information

Drug NameRituximab biosimilar (CTTQ Pharma)
Drug Alias Name利妥昔单抗生物仿制药（正大天晴）TQB-2303
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsLymphoma, T-Cell +[10] 
Global Approved IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2023/05/26
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer CenterNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group +[4] 
Inactive CompaniesRutgers University
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsLymphoma, Follicular +[6] 
Inactive IndicationsLymphoma, T-CellLymphoma, Mantle-CellLymphoma, B-Cell +[4] 

Other Information

ATC CodeL01XC02
Related LinksN/A